Does Semaglutide Target Belly Fat? What the Research Shows

*Compounded semaglutide is not FDA-approved. This article is for educational and informational purposes only and does not constitute medical advice. Individual results vary. Always consult your licensed healthcare provider before starting, stopping, or changing any weight management treatment.*

---

When people start semaglutide, the question they often ask is not "will I lose weight?" The answer to that one is fairly well established. The question they really want answered is: "Will I finally lose the belly?"

It is a reasonable thing to wonder. Belly fat can feel like a permanent fixture, stubborn in ways that thighs or arms are not. Many people lose weight over the years only to find their waist barely changes. So when a medication produces meaningful overall weight loss, it matters whether that loss includes the abdomen, or whether the belly just sits there while everything else shrinks.

Here is what the research actually shows.

---

Not All Belly Fat Is the Same

Before getting into semaglutide specifically, it helps to understand that belly fat is not a single thing. There are two distinct types sitting in your midsection, and they behave very differently.

The first is subcutaneous fat. This is the fat you can physically grab, the soft layer sitting just beneath your skin. In modest amounts, it is metabolically unremarkable. You can have quite a bit of it without facing significant health consequences.

The second is visceral fat. This type sits deep inside the abdominal cavity, surrounding your liver, pancreas, and intestines. You cannot feel it from the outside. It does not jiggle. But it is the kind that matters most to your health.

Visceral fat is metabolically active in ways subcutaneous fat is not. It releases inflammatory compounds and free fatty acids directly into the blood supply feeding your liver. Over time, this drives insulin resistance, raises triglycerides, contributes to non-alcoholic fatty liver disease, and significantly raises cardiovascular risk. A large waist circumference (generally defined as over 40 inches in men and over 35 inches in women) is used clinically as a proxy for excess visceral fat, even when total body weight looks normal.

This is the fat most worth reducing. And it turns out, it is also the fat most responsive to caloric restriction and GLP-1 receptor agonists like semaglutide.

---

What the Research Shows

CT Imaging Studies

One of the most direct ways to measure visceral fat change is computed tomography (CT) imaging, which can precisely quantify visceral adipose tissue area. A 2024 study published in the *AJR American Journal of Roentgenology* used automated AI-based CT analysis to track body composition in 241 patients who initiated semaglutide therapy. [1] In the group that lost weight on the medication, visceral fat area decreased from an average of 341.1 cm² to 309.1 cm², a meaningful reduction in the deep abdominal fat that carries the highest metabolic risk.

The same study found corresponding reductions in liver volume and improved liver quality markers, which is consistent with what you would expect when visceral fat decreases: less fat draining into the liver, reduced hepatic fat accumulation.

The STEP Trials: Weight Loss and Waist Circumference

The large STEP clinical trial program enrolled thousands of adults in placebo-controlled studies of semaglutide 2.4 mg weekly. The STEP 1 trial, published in the *New England Journal of Medicine* in 2021, followed 1,961 adults with overweight or obesity over 68 weeks. [2] Participants on semaglutide lost an average of 14.9% of their body weight. The trial also tracked waist circumference, which fell significantly in the semaglutide group compared to placebo.

Waist circumference is a standard surrogate for visceral adiposity in large clinical trials, because MRI or CT imaging on thousands of participants is not practical. The consistent waist reductions seen across the STEP program suggest visceral fat is indeed responding.

The STEP 5 trial extended follow-up to two years in a subset of participants. Published in *Nature Medicine* in 2022, it found that weight loss of 15.2% on average was maintained at 104 weeks. [3] This matters for belly fat because visceral fat loss is unlikely to be isolated to the first few months. Sustained weight loss typically means sustained visceral fat reduction.

Body Composition Substudy Data

A substudy of the SUSTAIN 8 trial, published in *Diabetologia* in 2020, used DEXA scans to directly measure body composition in 178 adults with type 2 diabetes on once-weekly semaglutide versus once-daily canagliflozin. [4] Semaglutide reduced total fat mass by 3.4 kg over 52 weeks. While this substudy enrolled people with diabetes (who may respond somewhat differently than people without diabetes), it provides direct evidence that fat mass, not just water weight or lean mass, is what semaglutide primarily removes.

---

Why Visceral Fat May Respond Preferentially

The biology here is worth understanding briefly, because it explains why the belly tends to be one of the first places people notice a difference on semaglutide.

Visceral fat cells carry more beta-adrenergic receptors than subcutaneous fat cells. This means they respond more aggressively to catecholamines (the hormones released during energy deficit) and are mobilized more readily when your body needs to burn stored energy. When semaglutide reduces appetite and overall caloric intake, the energy deficit that results tends to draw disproportionately from visceral stores in the early months.

There is also the insulin piece. Semaglutide improves insulin sensitivity, and excess insulin is one of the key drivers of visceral fat accumulation. GLP-1 receptor agonists reduce the postprandial insulin spikes that follow meals, creating a hormonal environment less favorable to fat storage in the visceral depot.

Finally, there is the hepatic fat connection. GLP-1 receptors are present in the liver. Semaglutide appears to directly support fatty acid oxidation in hepatocytes, which may accelerate the clearance of fat from the liver and the portal circulation that feeds it. Less fat cycling through the liver means less visceral fat deposition over time.

---

What You Will Likely Notice and When

In clinical practice, many patients on semaglutide report noticing their waist and abdomen changing before other areas. This is consistent with what the biology would predict. Visceral fat is more metabolically active, more responsive to energy deficit, and closer to the GLP-1 receptor systems that semaglutide directly targets.

The timeline varies by individual. Most people begin to notice clothing fitting differently around the waist within the first six to twelve weeks on a therapeutic dose. The scale and waist circumference changes tend to track together during this period. After the initial months, overall body fat continues to decrease, though the rate typically slows.

One important note: semaglutide does not spot-reduce fat in any strict sense. It creates a caloric deficit that your body responds to in a specific physiological sequence, with visceral fat tending to mobilize early and readily. Subcutaneous fat, including the visible softness around the lower belly, often takes longer and responds more slowly than visceral fat does. Patients sometimes notice their health markers improving (blood pressure, fasting glucose, triglycerides) well before they see the changes they were hoping for in the mirror.

---

How to Get the Most from Belly Fat Reduction on Semaglutide

The research supports several strategies that work alongside semaglutide to accelerate visceral fat loss specifically.

Prioritize protein intake. Adequate dietary protein (generally 1.2 to 1.6 grams per kilogram of body weight daily) preserves lean muscle during weight loss. Maintaining muscle mass matters because muscle is metabolically active tissue. When you protect it, a greater proportion of your weight loss comes from fat, including visceral fat.

Add resistance training. Aerobic exercise burns calories. Resistance training rebuilds and preserves the muscle tissue at risk during a caloric deficit. Studies consistently show that combining resistance exercise with weight-loss interventions improves body composition outcomes compared to caloric restriction or medication alone.

Manage cortisol. Chronic stress raises cortisol levels, and cortisol is one of the primary hormonal drivers of visceral fat accumulation. Sleep deprivation has a similar effect. Getting seven to nine hours of sleep per night and actively managing stress supports the hormonal environment in which visceral fat is more likely to mobilize.

Limit alcohol. Alcohol is processed by the liver and has a direct relationship with visceral fat deposition. Even moderate alcohol consumption can blunt the improvements in liver fat and visceral adiposity that semaglutide is working to produce.

None of these are requirements. Semaglutide works on its own. But the people who see the most significant improvements in waist circumference are typically the ones treating the medication as a foundation rather than a complete solution.

---

A Note on Compounded Semaglutide

The semaglutide available through telehealth programs like Prescriva is a compounded formulation, prepared by 503A licensed pharmacies. Compounded semaglutide is not FDA-approved and has not undergone the same approval process as branded Wegovy or Ozempic. It is prescribed as part of a medically supervised program and should only be used under the guidance of a licensed healthcare provider.

The clinical studies referenced in this article used FDA-approved semaglutide formulations. The mechanism of action is the same (GLP-1 receptor agonism), but the body of long-term safety data applies specifically to the approved products. Talk to your provider about whether compounded semaglutide is appropriate for your situation.

---

The Short Answer

Semaglutide does reduce belly fat. The CT imaging research shows measurable decreases in visceral fat area. The clinical trials show meaningful waist circumference reductions alongside overall weight loss. The biology supports the idea that visceral fat is among the most responsive fat depots when GLP-1 receptor agonists reduce appetite and caloric intake.

Will semaglutide make your belly flat? That depends on how much belly fat you carry, how your body distributes weight loss, and how long you stay on treatment. What the research supports is that the fat reduction is real, the belly is not being skipped, and for most people, it is one of the first places they notice results.

---

*This is not medical advice. If you are considering semaglutide or have questions about whether it is right for you, speak with a licensed healthcare provider who can evaluate your full medical history.*

Ready to explore your options? [Check your eligibility at Prescriva.](/assessment)

---

Sources

1. Nelson LW, et al. "Intrapatient Changes in CT-Based Body Composition After Initiation of Semaglutide Therapy." *AJR American Journal of Roentgenology.* 2024. [PMID: 39230989](https://pubmed.ncbi.nlm.nih.gov/39230989/)

1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." *New England Journal of Medicine.* 2021;384(11):989-1002. [PMID: 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)

1. Garvey WT, et al. "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial." *Nature Medicine.* 2022;28(10):2083-2091. [PMID: 36216945](https://pubmed.ncbi.nlm.nih.gov/36216945/)

1. McCrimmon RJ, et al. "Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial." *Diabetologia.* 2020;63(3):473-485. [PMID: 31897524](https://pubmed.ncbi.nlm.nih.gov/31897524/)